One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a huge buy on Tuesday. Specifically, this fund bought roughly $7.3 million worth of Ginkgo Bioworks Holdings Inc. (NYSE: DNA), as the prices of this fund was down slightly on Tuesday.
[in-text-ad]
ARK Innovation ETF (NYSEARCA: ARKK) bought 764,703 shares of Ginkgo Bioworks. At Tuesday’s closing price, this would have valued the sale at roughly $7.3 million. Even though this is a small fraction of their total holdings, every little bit counts. The Innovation ETF is down over 23% in the past year.

Check out all the ARK Invest purchases for Tuesday as well:

Fund	Ticker	Name	Shares
ARKF	TCSLI	TCS GROUP	73,600
ARKF	DSYSJ	DISCOVERY	29,478
ARKG	VCYT	VERACYTE	45,700
ARKG	SLGC	SOMALOGIC	187,013
ARKG	SDGR	SCHRODINGER	12,216
ARKG	QSI	QUANTUM-SI	51,318
ARKG	PSNL	PERSONALIS	100,496
ARKG	NTLA	INTELLIA THERAPEUTICS	20,655
ARKG	MASS	908 DEVICES	20,047
ARKG	FATE	FATE THERAPEUTICS	196,581
ARKG	ACCD	ACCOLADE	116,240
ARKG	BLI	BERKELEY LIGHTS	44,000
ARKK	SSYS	STRATASYS	72,471
ARKK	NVTA	INVITAE	18,000
ARKK	NTLA	INTELLIA THERAPEUTICS	8,433
ARKK	MTLS	MATERIALISE	32,775
ARKK	DNA	GINKGO BIOWORKS	764,703
ARKQ	XPEV	XPENG	97,697
ARKQ	VUZI	VUZIX	32,182
ARKQ	BLDE	BLADE AIR MOBILITY	44,068
ARKW	COIN	COINBASE GLOBAL	11,761
ARKW	EDR	ENDEAVOR GROUP	177,885
ARKW	VCYT	VERACYTE	50,910
ARKW	ROKU	ROKU	7,188
ARKX	AVAV	AEROVIRONMENT	16,273
ARKX	GRMN	GARMIN	8,728
ARKX	MYNA	MYNARIC	4,707

Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.